VASO Corp: Form 10-Q for the period ended Sep 30, 2024
Filed with the SEC on Nov 14, 2024 and accepted by EDGAR at Nov 14, 2024, 16:00 ET.
Management's discussion and analysis
As filed, 28,322 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: unfavorable business and economic conditions; the effect of pandemics and geopolitical events, including the COVID-19 pandemic which has adversely affected our operating results; the ability to keep pace with the dramatic changes taking place in IT and healthcare; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; securing and protecting our intellectual property rights; compliance with applicable government regulations; failure to maintain the integrity of our information technology systems, including without limitation, cyber-attacks; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; continuation of the GEHC agreement; our ability to enter into new partnerships and strategic transactions, and the risk factors reported from time to time in the Company’s SEC reports, including its recent report on Form 10-K. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.
General Overview
Our Business Segments
Vaso Corporation (“Vaso”) was incorporated in Delaware in July 1987. We principally operate in three distinct business segments in the healthcare and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
- IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services;
- Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and
- Equipment segment, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively.
Termination of Business Combination Agreement
On September 17, 2024 Vaso provided notice to Achari to terminate the Business Combination Agreement with Achari. Vaso intends to continue to seek opportunities to increase stockholder value, including through internal growth, new partnerships, and strategic investments with a concentration on medical and IT service companies.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.
Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see Note B to the condensed consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on April 1, 2024.
Results of Operations – For the Three Months Ended September 30, 2024 and 2023
Revenues
Total revenue for the three months ended September 30, 2024 and 2023 was $20,769,000 and $19,449,000, respectively, representing an increase of $1,320,000, or 7% year-over-year. On a segment basis, revenue in the IT and professional sales services segments increased by $1,215,000 and $277,000, respectively, while revenue in the equipment segment decreased by $172,000.
Revenue in the IT segment for the three months ended September 30, 2024 was $11,082,000 compared to $9,867,000 for the three months ended September 30, 2023, an increase of $1,215,000, or 12%, of which $1,133,000 resulted from higher network services revenue and $82,000 from higher revenues in the healthcare IT business. Monthly recurring revenue in the IT segment accounted for $9,341,000 or 84% of the segment revenue in the third quarter of 2024, and $9,302,000 or 94% of the segment revenue for the same quarter last year (see Note C).
Commission revenues in the professional sales service segment were $9,114,000 in the third quarter of 2024, an increase of $277,000, or 3%, as compared to $8,837,000 in the same quarter of 2023. The increase in commission revenues was due primarily to both an increase in the volume of underlying equipment delivered by GEHC during the period and a higher blended commission rate applicable to such deliveries. The Company only recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GEHC prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of September 30, 2024, $33,117,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $15,623,000 was long-term. As of September 30, 2023, $33,232,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $14,701,000 was long-term. The small decrease in deferred revenue is principally due to high deliveries in the 4th quarter of 2023, partially offset by an increase in new orders booked in 2024.
Revenue in the equipment segment decreased by $172,000, or 23%, to $573,000 for the three-month period ended September 30, 2024 from $745,000 for the same period of the prior year, due to lower ARCS® subscription revenues in our US operations as well as lower deliveries in our China operations.
Gross Profit
Gross profit for the three months ended September 30, 2024 and 2023 was $11,756,000, or 57% of revenue, and $12,043,000, or 62% of revenue, respectively, representing a decrease of $287,000, or 2% year-over-year. On a segment basis, gross profit in the professional sales service segment increased $75,000, or 1%, while gross profit in the IT and equipment segments decreased $163,000, or 4%, and $199,000, or 35%, respectively.
IT segment gross profit for the three months ended September 30, 2024 was $4,111,000, or 37% of the segment revenue, compared to $4,274,000, or 43% of the segment revenue for the three months ended September 30, 2023. The year-over-year decrease of $163,000, or 4%, was primarily a result of a lower margin sales mix in the network services business.
Professional sales service segment gross profit was $7,276,000, or 80% of segment revenue, for the three months ended September 30, 2024 as compared to $7,201,000, or 81% of the segment revenue, for the three months ended September 30, 2023, reflecting an increase of $75,000, or 1%. The increase was due to higher commission revenue as a result of higher volume of GEHC equipment delivered during the third quarter of 2024 and a higher blended commission rate, when compared to the same period last year, partially offset by higher commission expenses. Cost of commissions in the professional sales service segment of $1,838,000 and $1,636,000, for the three months ended September 30, 2024 and 2023, respectively, reflected commission expense associated with recognized commission revenues.
Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the balance sheet until the related commission revenue is recognized.
Equipment segment gross profit decreased to $369,000, or 64% of segment revenues, for the third quarter of 2024 compared to $568,000, or 76% of segment revenues, for the same quarter of 2023. The $199,000, or 35%, decrease in gross profit was primarily the result of lower sales and a lower gross margin for product sales in China during the quarter.
Operating Income (Loss)
Operating income (loss) for the three months ended September 30, 2024 was $(1,393,000) compared to $907,000 for the same quarter in 2023, representing a decrease of $2,300,000, or 254%, due primarily to $1,409,000 higher costs for investment banking activities, and to both the decrease in gross profit and the increase in operating costs (below) in the IT segment. On a segment basis, the IT segment recorded an operating loss of $695,000 in the third quarter of 2024 as compared to an operating loss of $187,000 in the same period of 2023; the professional sales service segment recorded operating income of $1,531,000 in the third quarter of 2024 as opposed to operating income of $1,648,000 in the same period of 2023; and the equipment segment recorded an operating loss of $223,000 in the third quarter of 2024 as compared to an operating loss of $83,000 in the same period of 2023.
Operating loss in the IT segment increased to $695,000 for the three-month period ended September 30, 2024 from an operating loss of $187,000 in the same period of 2023, due to lower gross profit and higher SG&A costs. Operating income in the professional sales service segment decreased by $117,000 in the three-month period ended September 30, 2024 as compared to operating income in the same period of 2023, due to higher SG&A costs, partially offset by higher gross profit. The equipment segment reported an operating loss of $223,000 in the third quarter of 2024, compared to an operating loss of $83,000 in the third quarter 2023, an increase of $140,000, primarily due to lower gross profit partially offset by lower SG&A costs in both US and China operations.
SG&A costs for the three months ended September 30, 2024 and 2023 were $11,409,000 and $10,887,000, respectively, representing an increase of $522,000, or 5% year-over-year. On a segment basis, SG&A costs in the IT segment increased by $346,000 in the third quarter of 2024 from the same quarter of the prior year due primarily to higher personnel costs; SG&A costs in the professional sales service segment increased $191,000 due mainly to higher personnel costs associated with provision of expanded services; and SG&A costs in the equipment segment decreased $41,000 due primarily to lower personnel costs. Corporate SG&A costs not allocated to segments increased $26,000 due mainly to higher annual meeting costs, partially offset by lower directors’ fees. Investment banking expenses for the business combination with Achari Venture Holdings I increased to $1,549,000 in the third quarter of 2024 from $40,000 in the third quarter of 2023.
Research and development expenses were $191,000, or 1% of revenues, for the third quarter of 2024, a decrease of $79,000, or 9%, from $209,000, or 1% of revenues, for the third quarter of 2023. The decrease is primarily attributable to lower product development expenses in the equipment segment.
Adjusted EBITDA
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes. We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for operating income, which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
A reconciliation of net income (loss) to Adjusted EBITDA is set forth below:
(in thousands)
(unaudited)
(unaudited)
| Three months ended September 30, 2024 | 2023 | |
|---|---|---|
| Net (loss) income | $(1,181) | $1,198 |
| Interest expense (income), net | (284) | (264) |
| Income tax expense | 30 | 16 |
| Depreciation and amortization | 219 | 225 |
| Share-based compensation | 8 | 10 |
| Adjusted EBITDA | $(1,208) | $1,185 |
Adjusted EBITDA decreased by $2,393,000, to $(1,208,000) in the quarter ended September 30, 2024 from $1,185,000 in the quarter ended September 30, 2023. The decrease was primarily attributable to the decrease in net income and increase in interest income.
Interest and Other Income (Expense)
Interest and other income (expense) for the three months ended September 30, 2024 was $242,000 as compared to $307,000 for the corresponding period of 2023. The decrease in interest and other income (expense) was due primarily to higher loss at EECP Global, partially offset by higher interest income resulting from higher money market and US Treasury bill balances.
Income Tax Expense
For the three months ended September 30, 2024, we recorded income tax expense of $30,000 as compared to $16,000 for the corresponding period of 2023. The $14,000 increase is due mainly to higher state tax expense.
Net Income (Loss)
Net loss for the three months ended September 30, 2024 was $1,181,000 as compared to net income of $1,198,000 for the three months ended September 30, 2023, representing a decrease of $2,379,000. Income (loss) per share of $(0.01) and $0.01 was recorded in the three-month periods ended September 30, 2024 and 2023, respectively. The principal cause of the decrease in net income is the increase in business combination transaction costs, decrease in gross profit and increase in SG&A costs, partially offset by the increase in interest income.
Results of Operations – For the Nine Months Ended September 30, 2024 and 2023
Revenues
Total revenue for the nine months ended September 30, 2024 and 2023 was $59,732,000 and $59,107,000, respectively, representing an increase of $625,000, or 1% year-over-year. On a segment basis, revenue in the IT segment increased $1,249,000, while revenue in the professional sales service and equipment segments decreased $51,000 and $573,000, respectively.
Revenue in the IT segment for the nine months ended September 30, 2024 was $31,825,000 compared to $30,576,000 for the nine months ended September 30, 2023, an increase of $1,249,000, or 4%, of which $1,561,000 resulted from higher network services revenue, offset by $312,000 lower revenue from healthcare IT services. Our monthly recurring revenue in the IT segment accounted for $27,445,000 or 86% of the segment revenue in the first nine months of 2024, and $28,180,000 or 92% of the segment revenue for the same period last year (see Note C).
Commission revenues in the professional sales service segment were $26,350,000 in the first nine months of 2024, a decrease of $51,000, or less than 1%, as compared to $26,401,000 in the first nine months of 2023. The decrease in commission revenues was due primarily to a slight decrease in the volume of underlying equipment delivered by GEHC during the period, offset by a higher blended commission rate applicable to such deliveries. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GEHC prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of September 30, 2024, $33,232,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $14,701,000 was long-term. As of September 30, 2023, $33,232,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $14,701,000 was long-term. The small decrease in deferred revenue is principally due to high deliveries in the 4th quarter of 2023, partially offset by an increase in new orders booked in 2024.
Revenue in the equipment segment decreased by $573,000, or 27%, to $1,557,000 for the nine-month period ended September 30, 2024 from $2,130,000 for the same period of the prior year, principally due to lower equipment deliveries in our China operations and lower cloud-based software-as-a-service (“SaaS”) sales in the U.S.
Gross Profit
Gross profit for the nine months ended September 30, 2024 and 2023 was $34,824,000, or 58% of revenue, and $36,540,000, or 62% of revenue, respectively, representing a decrease of $1,716,000, or 5% year-over-year. On a segment basis, gross profit in the IT, professional sales service, and equipment segments decreased $569,000, or 4%; $653,000, or 3%; and $494,000, or 31%, respectively.
IT segment gross profit for the nine months ended September 30, 2024 was $12,886,000, or 40% of the segment revenue, compared to $13,455,000, or 44% of the segment revenue for the nine months ended September 30, 2023. The year-over-year decrease of $569,000, or 4%, was primarily a result of lower margin product sales mix in both the network service and healthcare IT businesses, partially offset by higher network service revenues.
Professional sales service segment gross profit was $20,827,000, or 79% of segment revenue, for the nine months ended September 30, 2024 as compared to $21,480,000, or 81% of the segment revenue, for the nine months ended September 30, 2023, reflecting a decrease of $653,000, or 3%. The decrease was primarily due to the product mix of diagnostic imaging revenues and ultrasound revenues, where ultrasound revenues incur higher cost of commissions. Cost of commissions in the professional sales service segment of $5,523,000 and $4,921,000, for the nine months ended September 30, 2024 and 2023, respectively, reflected commission expense associated with recognized commission revenues.
Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the balance sheet until the related commission revenue is recognized.
Equipment segment gross profit decreased to $1,111,000, or 71% of segment revenues, for the first nine months of 2024 compared to $1,605,000, or 75% of segment revenues, for the same period in 2023. The $494,000, or 31%, decrease in gross profit was primarily the result of lower revenue in both our China operations and our U.S. SaaS operations, and by lower gross profit margin.
Operating Income (Loss)
Operating income (loss) for the nine months ended September 30, 2024 and 2023 was $(1,866,000), and $3,225,000, respectively, representing a decrease of $5,091,000 as a combined result of gross profit decreasing $1,716,000 and operating costs (below) increasing $3,375,000, year-over-year. On a segment basis, the IT segment recorded an operating loss of $1,288,000 in the first nine months of 2024 as compared to an operating loss of $133,000 in the same period of 2023; operating income in the professional sales service segment decreased by $1,602,000, from $4,784,000 in the first nine months of 2023 to $3,182,000 in the same period of 2024; and the equipment segment recorded an operating loss of $809,000 in the first nine months of 2024 as compared to an operating loss of $214,000 in the same period of 2023.
Operating loss in the IT segment increased to $1,288,000 for the nine-month period ended September 30, 2024 as compared to an operating loss of $133,000 in the same period of 2023, due primarily to lower gross profit and higher SG&A costs. Operating income in the professional sales service segment decreased $1,602,000 to $3,182,000 in the nine-month period ended September 30, 2024 as compared to operating income of $4,784,000 in the same period of 2023, due to higher SG&A costs and lower gross profit. The equipment segment reported an operating loss of $809,000 in the first nine months of 2024, compared to an operating loss of $214,000 in the first nine months of 2023, an increase of $494,000, due mainly to lower gross profit, as well as to higher SG&A and R&D costs.
SG&A costs for the nine months ended September 30, 2024 and 2023 were $34,316,000 and $32,691,000, respectively, representing an increase of $1,625,000, or 5% year-over-year. On a segment basis, SG&A costs in the IT segment increased by $605,000 in the first nine months of 2024 from the same period of the prior year due mainly to higher personnel costs; SG&A costs in the professional sales service segment increased by $948,000 due to higher personnel costs associated with the provision of expanded services, and to higher travel costs; and SG&A costs in the equipment segment increased by $78,000 due mainly to higher personnel costs. Corporate SG&A costs not allocated to segments decreased $7,000 due mainly to lower director fees and insurance costs, partially offset by higher annual meeting costs. Expenses for investment banking activities associated with the business combination with Achari Venture Holdings I increased to $1,787,000 in the nine months ended September 30, 2024 from $40,000 in the same period of 2023.
Research and development (“R&D”) expenses were $587,000, or 1% of revenues, for the first nine months of 2024, an increase of $3,000, or less than 1%, from $584,000, or 1% of revenues, for the first nine months of 2023. The increase is primarily attributable to higher product development expenses in the equipment segment.
Adjusted EBITDA
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes. We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for operating income, which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
A reconciliation of net income (loss) to Adjusted EBITDA is set forth below:
(in thousands)
(unaudited)
(unaudited)
| Nine months ended September 30, 2024 | 2023 | |
|---|---|---|
| Net (loss) income | $(1,199) | $3,724 |
| Interest expense (income), net | (884) | (555) |
| Income tax expense | 154 | 35 |
| Depreciation and amortization | 630 | 762 |
| Share-based compensation | 26 | 38 |
| Adjusted EBITDA | $(1,273) | $4,004 |
Adjusted EBITDA decreased by $5,277,000 to $(1,273,000) in the nine months ended September 30, 2024 from $4,004,000 in the nine months ended September 30, 2023. The decrease was primarily attributable to lower net income and higher interest income, partially offset by higher income tax expense.
Interest and Other Income (Expense)
Interest and other income (expense) for the nine months ended September 30, 2024 was $821,000 as compared to $534,000 for the corresponding period of 2023. The increase in interest and other income was due primarily to higher interest income.
Income Tax Expense
For the nine months ended September 30, 2024, we recorded income tax expense of $154,000 as compared to income tax expense of $35,000 for the corresponding period of 2023. The increase was due mainly to higher state tax expense.
Net Income (Loss)
Net loss for the nine months ended September 30, 2024 was $1,199,000 as compared to net income of $3,724,000 for the nine months ended September 30, 2023, representing a decrease of $4,923,000, or 132%. Income (loss) per share of $(0.01) and $0.02 was recorded in the nine-month periods ended September 30, 2024 and 2023, respectively. The principal cause of the decrease was lower operating income, partially offset by higher interest income.
Liquidity and Capital Resources
Cash and Cash Flow
We have financed our operations from working capital. At September 30, 2024, we had cash and cash equivalents of $26,841,000 and working capital of $12,822,00 0, compared to cash and cash equivalents of $11,342,000 and working capital of $15,059,000 at December 31, 2023.
Cash provided by operating activities was $3,648,000, which consisted of net loss after adjustments to reconcile net loss to net cash of $287,000 and cash provided by operating assets and liabilities of $3,361,000, during the nine months ended September 30, 2024, compared to cash provided by operating activities of $6,860,000 for the same period in 2023. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $4,111,000 and increases in accounts payables and deferred revenue of $1,886,000 and $921,000, respectively; partially offset by decreases in accrued commissions and accrued expenses of $1,092,000 and $2,439,000, respectively.
Cash provided by investing activities during the nine-month period ended September 30, 2024 was $11,953,000 attributed to $13,757,000 in redemption of short-term investments, offset by $1,231,000 used for the purchase of equipment and software and $573,000 used in the funding of a working capital loan to Achari.
Cash used in financing activities during the nine-month period ended September 30, 2024 was $67,000 resulting primarily from the repayment of notes payable and finance lease obligations.
Liquidity
The Company expects to generate sufficient cash flow from operations to satisfy its obligations for at least the next twelve months.
Controls and procedures
As filed, 1,477 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2024 and have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2024.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal control over financial reporting during the Company’s fiscal quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-07-01 to 2024-09-30 | $20.8m | us-gaap:Revenues |
| Revenue | 9 months2024-01-01 to 2024-09-30 | $59.7m | us-gaap:Revenues |
| Cost of revenue | 3 months2024-07-01 to 2024-09-30 | $9.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2024-01-01 to 2024-09-30 | $24.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2024-07-01 to 2024-09-30 | $11.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-01-01 to 2024-09-30 | $34.8m | us-gaap:GrossProfit |
| Research and development | 3 months2024-07-01 to 2024-09-30 | $191.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-01-01 to 2024-09-30 | $587.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2024-07-01 to 2024-09-30 | $11.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-01-01 to 2024-09-30 | $34.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-07-01 to 2024-09-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-01-01 to 2024-09-30 | −$1.9m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-07-01 to 2024-09-30 | $30.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-01-01 to 2024-09-30 | $154.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-07-01 to 2024-09-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-01-01 to 2024-09-30 | −$1.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-07-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-01-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-07-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-01-01 to 2024-09-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-07-01 to 2024-09-30 | 175,471,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-01-01 to 2024-09-30 | 175,319,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-01-01 to 2024-09-30 | $3.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-09-30 | $26.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-09-30 | $43.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-09-30 | $73.9m | us-gaap:Assets |
| Current liabilities | At period end2024-09-30 | $30.2m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | At period end2024-09-30 | $25.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-24-098378. Last ingested by Listed: Oct 29, 2026, 13:52 ET. Listed shows no prices and gives no investment advice.